Tecentriq and Dermatomyositis - a phase IV clinical study of FDA data

Summary:

Dermatomyositis is reported as a side effect among people who take Tecentriq (atezolizumab), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Carboplatin, and have Lung cancer - small cell.

The phase IV clinical study analyzes which people have Dermatomyositis when taking Tecentriq. It is created by eHealthMe based on reports of 12,792 people who have side effects when taking Tecentriq from the FDA, and is updated regularly.

What is Tecentriq?

Tecentriq has active ingredients of atezolizumab. eHealthMe is studying from 12,796 Tecentriq users. Check the latest studies of Tecentriq.

What is Dermatomyositis?

Dermatomyositis (inflammation of the skin and underlying muscle tissue, typically occurring as an autoimmune condition or associated with internal cancer) is found to be associated with 261 drugs and 416 conditions by eHealthMe. Check the latest studies of Dermatomyositis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

12,792 people reported to have side effects when taking Tecentriq.
Among them, 16 people (0.13%) have Dermatomyositis.

Among these 16 people:

How long have people been on Tecentriq when they have Dermatomyositis? *

What is the gender of people who have Dermatomyositis when taking Tecentriq? *

female: 37.5 %
male: 62.5 %

What is the age of people who have Dermatomyositis when taking Tecentriq? *

What are other drugs people take besides Tecentriq? *

Etoposide: 6 people, 37.50%
Carboplatin: 6 people, 37.50%
Avastin: 2 people, 12.50%
Abraxane: 1 person, 6.25%

What are other side effects people have besides Dermatomyositis? *

Weakness: 1 person, 6.25%
Swallowing Difficulty: 1 person, 6.25%
Respiratory Acidosis (respiratory failure or ventilatory failure, causes the ph of blood and other bodily fluids to decrease): 1 person, 6.25%
Renal Impairment (severely reduced kidney function): 1 person, 6.25%
Rashes (redness): 1 person, 6.25%
Pneumonia Aspiration (bronchopneumonia that develops due to the entrance of foreign materials into the bronchial tree): 1 person, 6.25%
Liver Disorder (liver diseases): 1 person, 6.25%
Interstitial Lung Disease: 1 person, 6.25%
Diarrhea: 1 person, 6.25%
Dehydration (dryness resulting from the removal of water): 1 person, 6.25%

What are the existing conditions these people have? *

Lung Cancer - Small Cell (lung cancer): 7 people, 43.75%
Small Cell Lung Cancer Metastatic (lung cancer spreads to other body parts): 2 people, 12.50%
Lung Cancer - Non-Small Cell (lung cancer): 2 people, 12.50%
Hepatocellular Carcinoma (liver cancer): 2 people, 12.50%
Small Cell Lung Cancer Extensive Stage (small cell lung cancer that has spread (metastasized) to other regions of the body such as another lobe of the lung or the brain): 1 person, 6.25%
Neuroendocrine Tumor: 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Tecentriq and have Dermatomyositis?

- Check whether Dermatomyositis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tecentriq:

Tecentriq (12,796 reports)

Dermatomyositis treatments and more:

Dermatomyositis (8,399 reports)

Browse all side effects of Tecentriq:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Dermatomyositis:

Dermatomyositis (261 drugs)

Browse all the conditions that are associated with Dermatomyositis:

Dermatomyositis (416 conditions)

Related publications that referenced our studies

Kato, M., Oiso, N., Nozaki, Y., Inoue, A., Hosono, Y., Funauchi, M., ... & Kawada, A., "Antitumor necrosis factor alpha inhibitor‐induced dermatomyositis and interstitial lung disease with anti‐PL 12 autoantibody: Signs of antisynthetase syndrome", The Journal of dermatology, 2012 Jan .
Kato, M., Oiso, N., Nozaki, Y., Inoue, A., Hosono, Y., Funauchi, M., ... & Kawada, A., "Antitumor necrosis factor alpha inhibitor‐induced dermatomyositis and interstitial lung disease with anti‐PL 12 autoantibody: Signs of antisynthetase syndrome", The Journal of dermatology, 2012 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on atezolizumab (the active ingredients of Tecentriq) and Tecentriq (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.